Moreover, our findings implicate the potential of applying 5-AcTMF to GBM treatment, either as a monotherapy drug or as a radio-/chemotherapies-sensitizing agent due to its inhibitory effect on STAT3 signaling. Here, STAT3 is linked to glioblastoma.